Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rehabilitation Intervention to Prevent Adverse Events Related to Androgen-deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer (PCa): a Single Arm Feasibility Study (ReCaP Study)

NCT06238596 is registered in ClinicalTrials.gov with Azienda USL Reggio Emilia - IRCCS as lead sponsor.

NCT NCT06238596
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06238596 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rehabilitation Intervention to Prevent Adverse Events Related to Androgen-deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer (PCa): a Single Arm Feasibility Study (ReCaP Study)
Lead sponsor
Azienda USL Reggio Emilia - IRCCS
Phase
Not applicable
Overall status
Completed
Start date
September 6, 2023
Completion date
May 29, 2026
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic prostate cancer (pca) in adt, rehabilitation